On March 28, 2017 Clovis Oncology, Inc. (NASDAQ: CLVS) reported that rucaparib preclinical data will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2017 (Press release, Clovis Oncology, MAR 28, 2017, View Source [SID1234518292]). AACR (Free AACR Whitepaper) will take place April 1-5, 2017 in Washington, DC. The data being presented provide greater insight into the mechanism of action and function of rucaparib in multiple disease and therapy settings. Schedule your 30 min Free 1stOncology Demo! "These data demonstrate Clovis Oncology’s commitment to fully understanding rucaparib’s mechanism of action as well as the therapeutic settings in which it may offer the most benefit to patients," said Patrick J. Mahaffy, President and CEO of Clovis Oncology.
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Rucaparib is the Company’s oral, potent, small molecule inhibitor of PARP1, PARP2 and PARP3. The FDA approved rucaparib (Rubraca) tablets in December 2016 for the monotherapy treatment of advanced ovarian cancer in women with deleterious germline or somatic BRCA mutations treated with two or more chemotherapies. Rucaparib is also being developed for other oncology indications in which patients may possess mutant BRCA tumors and other DNA repair deficiencies beyond BRCA – commonly referred to as homologous recombination deficiencies, or HRD.
Data from preclinical rucaparib studies are the subject of four poster presentations at the AACR (Free AACR Whitepaper) meeting:
Abstract 2475 – In vitro and in vivo assessment of the mechanism of action of the PARP inhibitor rucaparib
Presenter: Andrew J. Simmons, Ph.D., Translational Medicine, Clovis Oncology
Date/Time: Monday, April 3, 1:00-5:00 p.m. ET
Location: Halls A-C
Abstract 2476 – Preclinical assessment of the PARP inhibitor rucaparib in homologous recombination deficient prostate cancer models
Presenter: Minh Nguyen, Translational Medicine, Clovis Oncology
Date/Time: Monday, April 3, 1:00-5:00 p.m. ET
Location: Halls A-C
Abstract 3650 – Preclinical evaluation of the PARP inhibitor rucaparib in combination with PD-1 and PD-L1 inhibition in a syngeneic BRCA1 mutant ovarian cancer model
Presenter: Liliane Robillard, Translational Medicine, Clovis Oncology
Date/Time: Tuesday, April 4, 8:00 a.m.–12:00 p.m. ET
Location: Halls A-C
Abstract 4676 – DNA repair protein expression and response of homologous recombination deficient ovarian cancer to the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in the ARIEL2 Part 1 study
Presenter: Andrea E. Wahner Hendrickson, M.D., Assistant Professor of Oncology, Medical Oncology, Mayo Clinic, Rochester, Minnesota
Date/Time: Tuesday, April 4, 1:00-5:00 p.m. ET
Location: Halls A-C
Each presentation will be available online at View Source as of the time of presentation at the meeting.
About Rucaparib
Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in ovarian cancer as well as several additional solid tumor indications. The MAA submission in Europe for an ovarian cancer treatment indication was submitted and accepted during the fourth quarter of 2016. Additionally, rucaparib is being developed as maintenance therapy for ovarian cancer in the ARIEL3 trial for patients with tumors with BRCA mutations and other DNA repair deficiencies beyond BRCA, as well as biomarker negative patients. Data from ARIEL3 are expected in mid-2017, which, pending positive data, is expected to be followed by the submission of a supplemental NDA for a second line or later maintenance indication. Rucaparib is also being developed in patients with mutant BRCA tumors and other DNA repair deficiencies beyond BRCA – commonly referred to as homologous recombination deficiencies, or HRD. Studies open for enrollment or under consideration include prostate, breast, pancreatic, gastroesophageal, bladder and lung cancers. Clovis holds worldwide rights for rucaparib.